Oliceridine - Trevena

Drug Profile

Oliceridine - Trevena

Alternative Names: OLINVO; TRV-130; TRV130A

Latest Information Update: 14 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Trevena
  • Class Analgesics; Pyridines; Small molecules; Spiro compounds; Thiophenes
  • Mechanism of Action Beta arrestin inhibitors; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Postoperative pain
  • Phase II Pain

Most Recent Events

  • 07 Mar 2018 The US FDA sets PDUFA date of 02/11/2018 for NDA review for Oliceridine in Post operative pain
  • 07 Mar 2018 Trevena intends to launch OLINVO in USA in first quarter of 2019
  • 07 Mar 2018 Topline data from phase III ATHENA-1 trial in Post operative pain released by Trevena
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top